

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ruxin Wang^{1†}, Haowen Ye^{1†}, Li Ma², Jinjing Wei¹, Ying Wang¹, Xiaofang Zhang^{3*} and Lihong Wang^{1*}

OPEN ACCESS

Edited by:

Leon Ferder, Vice Chancellor Maimonides University Argentina, Argentina

Reviewed by:

Massimo Volpe, Sapienza University of Rome, Italy Emilia D'Elia, Papa Giovanni XXIII Hospital, Italy

*Correspondence:

Xiaofang Zhang 857154586@qq.com Lihong Wang nd6688@163.com [†]These authors have contributed

equally to this work

Specialty section:

This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine

> Received: 07 March 2022 Accepted: 25 April 2022 Published: 01 July 2022

Citation:

Wang R, Ye H, Ma L, Wei J, Wang Y, Zhang X and Wang L (2022) Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Cardiovasc. Med. 9:890481. doi: 10.3389/fcvm.2022.890481 ¹ Department of Endocrinology and Metabolism, The First Affiliated Hospital of Jinan University, Guangzhou, China, ² Department of Functional Examination, Gansu Provincial Maternal and Child Health Hospital, Lanzhou, China, ³ Clinical Experimental Center, The First Affiliated Hospital of Jinan University, Guangzhou, China

Background and Objective: Relevant data of PARADIGM-HF reveals sacubitril/valsartan (SV) therapy led to a greater reduction in the risks of arrhythmia, and sudden cardiac death than angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor inhibitor (ARB) therapy in HFrEF, however, inconsistent results were reported in subsequent studies. Here, we conduct a meta-analysis of related randomized controlled trials (RCTs) to evaluate the protective effect of SV on reducing the risk of arrhythmias.

Methods and Results: RCTs focused on the difference in therapeutic outcomes between SV and ACEI/ARB were searched from PUBMED, EMBASE, ClinicalTrials.gov, and Cochrane Library. The results were extracted from each individual study, expressed as binary risk, 95% confidence interval (CI) and relative risk (RR). Sixteen RCTs including 22, 563 patients met the study criteria. Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of severe arrhythmias among patients with heart failure with reduced ejection fraction (HFrEF) (RR 0.83, 95% CI 0.73–0.95, p = 0.006), ventricular tachycardia (VT) among patients with HFrEF (RR 0.69, 95% CI 0.51–0.92, p = 0.01), cardiac arrest among patients with heart failure (HF) (RR 0.52, 95% CI 0.37-0.73, p = 0.0002), cardiac arrest among patients with HFrEF (RR 0.49, 95% CI 0.32-0.76, p = 0.001), cardiac arrest or ventricular fibrillation (VF) among patients with HF (RR 0.63, 95% CI 0.48–0.83, p = 0.001), and cardiac arrest or VF among patients with HFrEF (RR 0.65, 95% Cl 0.47–0.89, p = 0.008), but reduced the risks of arrhythmias (RR 0.87, 95% CI 0.74–1.01, p = 0.07), atrial arrhythmias (RR 0.98, 95% CI 0.83– 1.16, p = 0.85), and atrial fibrillation (RR 0.98, 95% CI 0.82–1.17, p = 0.82) among all patients with no significant between-group difference. The merged result was robust after sensitivity analysis, and there was no publication bias.

Conclusion: Our meta-analysis provides evidence that, compared with ACEI/ARB, SV can additionally reduce the risks of most arrhythmias, just the significant differences are revealed in reducing the risks of VT, severe arrhythmias, and cardiac arrest in patients with HFrEF. Besides, the positive effect of SV on VF according to statistical result of combining VF with cardiac arrest in patients with HFrEF is credibility.

Keywords: sacubitril/valsartan, arrhythmia, atrial arrhythmia, ventricular arrhythmia, cardiac arrest, ACEI, ARB

INTRODUCTION

Arrhythmia is one of the most common diseases in cardiovascular field, which has complex relationships with multiple diseases (1), especially heart failure (HF). Destruction of normal periodicity and regularity of the electrical activity in heart has been recognized as the mechanism of arrhythmia. Atrial fibrillation (AF) and ventricular arrhythmia (VA) are common and serious in patients with HF, which can cause various complications and ultimately lead to disability or death, such as thrombus caused by AF, sudden cardiac death (SCD) caused by sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), etc. (2). The risk of AF has increased 3-fold in the world over the past 50 years based on the results of Framingham Heart Study (3), and the global prevalence of AF was about 46.3 million in 2016 according to the estimate of WHO (4). AF is the most common persistent arrhythmia with an average prevalence of 25% in HF (5), which can increase the risks of stroke and death (6). Sustained VA is a serious complication of HF, as it accounts for 75-80% of SCD, while about 30-50% of cardiovascular death in patients with HF was attributed to SCD (7). Arrhythmia is a challenging problem especially under the circumstance of HF, as their mutual interaction could further aggravating the state of an illness. Therefore, received widespread attention in terms of prevention, diagnosis, and treatment of arrhythmia. At present, a part of arrhythmias can be cured by new technologies with the wider application of interventional and surgical therapy (8), nevertheless, drug therapy is still currently the most important mean of the prevention and treatment of arrhythmias due to economic, scope of application of new technologies, etc.

prompted The data of PARADIGM-HF that sacubitril/valsartan (SV) therapy led to a greater reduction in the risk of SCD and significant survival benefit of SCD observed from the Kaplan-Meier curves than enalapril therapy among patients with heart failure with reduced ejection fraction (HFrEF), indicating SV may directly reduce the risk of SCD (9). Since then, the effect of SV on arrhythmia has attracted widespread concern. The effect of SV in arrhythmia is uncertain although it has been fully affirmed in HF and hypertension (10, 11). The researches of Russo et al. (12), Tsai et al. (13), and Curtain et al. (14) revealed that SV could improve ventricular remodeling while reducing the risk of VA compared with angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor inhibitor (ARB), meanwhile, it could improve atrial remodeling and atrial arrhythmia by the researches of Suo et al. (15) and Li et al. (16). Nevertheless, different results on arrhythmias were reported by El-Battrawy et al. (17), Martens

et al. (18), Solomon et al. (19), Velazquez et al. (20), and McMurray et al. (10), etc.

Thus far, few specifically studies about the effect of SV on arrhythmia have been investigated. The purpose of this metaanalysis is to provide some new approaches for the treatment of arrhythmia by analyzing the risks of arrhythmias in randomized controlled trials (RCTs) for SV.

MATERIALS AND METHODS

Search Strategy

We searched the Cochrane Library, Embase, PubMed and ClinicalTrials.gov, the current four major medical databases, which contain the vast majority of medical research literatures, as of February 21, 2022, and it was re-run twice on March 3, 2022. The search conditions include: sacubitril valsartan, sacubitril/valsartan, sacubitril, entresto, LCZ696, AHU377, angiotensin receptor neprilysin inhibitor, neprilysin inhibitor, sacubitril valsartan sodium hydrate, sacubitril valsartan drug combination. There was no protocol for expected registration, but the search terms, inclusion criteria, and data collection forms were pre-specified in the analysis plan and remain unchanged during data collection and analysis. The publication date and language restrictions were not applied, and reference lists of related articles were also used to supplement search terms. The study included only RCT.

Study Selection

The trials included in this study need to meet the following conditions: (1) The trial is an RCT. (2) The control group is intervened with ACEI/ARB, the experimental group is intervened with SV. (3) All studies must have data on adverse events endpoint or adverse reaction of arrhythmias.

Data Extraction

The two researchers independently extracted data from RCTs that met the criteria and Cochrane reviewer's handbook. In the event of discrepancies, all authors discussed the results. The research data was retrieved from the original published manuscript or the results in ClinicalTrials.gov. Extracted the following data from each trial: 1. Name of the trial, author, registration number; 2. year of publication; 3. number of people enrolled; 4. characteristics of participants at baseline, including arrhythmia, age, gender, etc.; 5. drug in control group; 6. study duration; 7. main outcome.

Quality Assessment

Two researchers separately assessed the risk of bias for each qualified trial by the Cochrane Collaboration's tool and compiled a bias risk table as described in Cochrane Handbook (21). The quality items used to evaluate each study were as follows: sequence generation of allocation, allocation concealment, blinding of participants, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other biases.

Outcome Measures

The number of arrhythmias listed in results of trials, including atrial arrhythmia, AF, VA, etc.

Statistical Analyses

Data of arrhythmias was analyzed by Review Manager 5.4, sensitivity analysis and publication bias detection by Stata 17.0, and I^2 was used to assess heterogeneity. $I^2 \ge 50\%$ or the corresponding *P*-value (p < 0.05) was considered to have obvious heterogeneity results and then we used a random model. $I^2 < 50\%$ and the corresponding *P*-value (p > 0.05) was considered to have no obvious heterogeneity results and then we used a fixed model (22). The results were extracted from each trial, expressed as binary risk, 95% confidence interval (CI), and relative risk (RR). The Mantel-Haenszel method and Z test were used to determine the overall results to determine the significance of RR. The heterogeneity was assessed with the



TABLE 1 | Characteristics of included RCTs.

Trial	Number	Follow-up	Patient	Inclusion criteria	Age (years)	Male (%)	Control	Dosage	Baseline arrhythmia (%)	Arrhythmia outcome (%)	Main outcome
EVALUATE-HF (29)	464	12 weeks	Hypertension with HFrEF	Age \geq 50 years, hypertension, CHF and EF \leq 40%, NYHA I-III	67.8 ± 9.8 vs. 66.7 ± 8.5	355 (77)	Enalapril	200 mg bid vs. 10 mg bid		Arrhythmia: 5 (2) vs. 0 (0) AA: 2 (0.9) vs. 0 (0) VA: 2 (0.9) vs. 0 (0) cardiac arrest: 0 (0) vs. 0 (0)	Treatment of HFrEF with SV, compared with enalapril, did not significantly reduce central aortic stiffness
NCT01785472 (30)	1,438	8 weeks	Hypertension	Mean sitting SBP ≥ 140 to < 180 mm Hg	$(57.5 \pm 10.17, 58.1 \pm 9.71)$ vs. 57.4 ± 10.14	756 (53)	Olmesartan	200/400 mg qd vs. 20 mg qd		Arrhythmia: 0 (0) vs. 1 (0.2) AA: 0 (0) vs. 1 (0.2)	Treatment with SV once daily is effective and provided superior BP reduction than olmesartan in Asian patients with mild-to-moderate hypertension
NCT01615198 (26)	588	14 weeks	Hypertension	Mean sitting SBP \geq 140 to < 180 mm Hg, aged \geq 65 years	70.5 ± 4.67 vs. 70.9 ± 4.67	294 (50)	Olmesartan	Starting dose: 100 mg qd vs. 10 mg qd maximum dose: 400 mg qd vs. 40 mg qd		Arrhythmia: 2 (0.7) vs. 0 (0) AA: 1 (0.3) vs. 0 (0)	SV is more effective than olmesartan in reducing BP in elderly Asian patients with systolic hypertension
NCT01599104 (31)	1,161	8 weeks	Hypertension	Japanese patients aged ≥ 20 years with mild to moderate systolic hypertension	(57.9 ± 10.9, 58.7 ± 10.5) vs. 59.6 ± 10.5	818 (70.5)	Olmesartan	200–400 mg qd vs. 20 mg qd		Arrhythmia: 0 (0) vs. 1 (0.3)	Treatment with SV was effective and provided superior BP reduction, with a higher proportion of patients achieving target BP goals than treatment with olmesartan in Japanese patients with mild to moderate essential hypertension
ACTIVITY-HF (32)	201	12 weeks	HFrEF	Aged \geq 18years with CHF [NYHA III and EF \leq 40%] and an objectively reduced exercise capacity (peak VO ₂ \leq 18 mL/min/kg%)	66.1 ± 10.8 vs. 67.6 ± 10.0	163 (81)	Enalapril	200 mg bid vs. 10 mg bid		Arrhythmia: 5 (0.5) vs. 4 (0.4) AA:2 (0.2) vs. 0 (0) VA: 2 (0.2) vs. 0 (0)	In patients with HFrEF, short-term treatment with SV for 12 weeks did not result in significant benefits on peak VO2 when compared with enalapril

TABLE 1 | (Continued)

Trial	Number	Follow-up	Patient	Inclusion criteria	Age (years)	male (%)	Control	Dosage	Baseline arrhythmia (%)	Arrhythmia outcome (%)	Main outcome
Wang Q (33)	149	3 months	HFpEF	Persistent AF (> 7 days or < 7 days but requiring electrical or pharmacological cardioversion) and HF symptoms	58.9 ± 12.75 vs. 62.7 ± 10.91	94 (68.12)	Valsartan	100 mg bid vs. 80 mg bid	All patients had AF	Arrhythmia: 15 (22) vs. 29 (42) AA: 15 (22) vs. 29 (42)	SV can decrease AF recurrence after catheter ablation in patients with persistent AF at the 1-year follow-up
Wang H (34)	137	24 weeks	HFrEF	Acute anterior STEMI, 18 years \leq age < 75 years, LVEF $<$ 45% and SBP \geq 100 mmHg	$\begin{array}{c} 59.13 \pm 7.15 \\ \text{vs.} \\ 60.56 \pm 7.62 \end{array}$	106 (77)	Enalapril	Starting dose: 50/100 mg bid vs. 2.5/5 mg bid		Arrhythmia: 6 (9) vs. 9 (13)	SV attenuated LV remodeling and dysfunction and was safe and effective in LV systolic dysfunction patients post-acute anterior wall myocardial infarction
PARAMOUNT (28)	301	3 months	HFpEF	NYHA II-III HFpEF,EF > 45%	70.9 ± 9.4 vs. 71.2 ± 8.9	152 (57)	Valsartan	200 mg bid vs. 160 mg bid	History of AF: 60 (40) vs. 65 (43) AF at screening: 40 (27) vs. 45 (30)	Arrhythmia: 5 (3) vs. 16 (11) AA:3 (2) vs. 9 (6)	SV has better effect on reducing BNP, improving LA reverse remodeling and NYHA compared with the valsartan in patients with HFpEF
PIONEER-HF (20)	881	8 weeks	HFrEF	Hemodynamic stabilization after ADHF and EF \leq 40%	61 (51, 71) vs. 63 (54, 72)	635 (72.1)	Enalapril	200 mg bid vs. 10 mg bid	AF: 147 (33.4) vs. 165 (37.4)	Arrhythmia: 13 (3) vs. 20 (5) AA: 6 (1) vs. 4 (1) VA: 5 (1) vs. 8 (2) cardiac arrest: 0 (0) vs. 4 (1)	Among patients with HFrEF who were hospitalized for ADHF, the initiation of SV therapy led to a greater reduction in the NT-proBNP concentration than enalapri therapy
PRIME (39)	118	12 months	HFrEF	NYHA II-III, EF > 25% and < 50%, significant functional MR lasting > 6 months	64.7 ± 10.2 vs. 60.5 ± 11.8	72 (61)	Valsartan	200 mg bid vs. 160 mg bid	AF: 15 (25.9) vs. 16 (26.7)	Arrhythmia: 0 (0) vs. 1 (2) VA:0 (0) vs. 1 (2)	Among patients with secondary functional MR, SV reduced MR to a greated extent than did valsartan
OUTSTEP-HF (36)	621	12 weeks	HFrEF	NYHA II and LVEF \leq 40%	66.89 ± 10.74	487 (79)	Enalapril	200 mg bid vs. 10 mg bid	AF: 147 (47.57) vs. 122 (39.35) SVT: 16 (5.18) vs. 9 (2.90)	Arrhythmia: 18 (6) vs. 19 (6) AA: 8 (3) vs. 6 (2) VA: 5 (1.6) vs. 2 (0.6) cardiac arrest: 0 (0) vs. 2 (0.6)	There was no significant benefit of SV either 6MWT or in daytime physical activity measured by actigraphy compared with enalapril
PARALLEL-HF (37)	223	33.9 months	HFrEF	NYHA II-IV and EF $\leq 35\%$	69.0 ± 9.7 vs. 66.7 ± 10.9	192 (86)	Enalapril	200 mg bid vs. 10 mg bid	AFL: 36 (32.4) vs. 40 (35.7)	Arrhythmia: 11 (10) vs. 12 (11) AA: 4 (4) vs. 4 (4) VA: 7 (6) vs. 8 (7)	In Japanese patients with HFrEF, there was no difference in reduction in the risk of cardiovascular death or HF hospitalization between SV and enalapril

(Continued)

Effect of Sacubitril/Valsartan on Arrhythmia

TABLE 1 | (Continued)

Trial	Number	Follow-up	Patient	Inclusion criteria	Age (years)	male (%)	Control	Dosage	Baseline arrhythmia (%)	Arrhythmia outcome (%)	Main outcome
PARALLAX (38)	2 566	24 weeks	HFpEF	NYHA II-IV, EF > 40%, LV hypertrophy or left atrial enlargement with NT-proBNP↑	73 ± 8.4 vs. 72 ± 8.6	1,265 (49)	Enalapril /valsartan	200 mg bid vs. 10 mg bid vs. 160 mg	AF or AFL: 699 (54.6) vs. 692 (53.9)	Arrhythmia: 10 (1) vs. 15 (1) AA: 10 (0.9) vs. 15 (1.3)	Among patients with HFpEF, SV treatment compared with standard renin angiotensin system inhibitor treatment or placebo resulted in a significantly greater decrease in NT-proBNP levels at 12 weeks but did not significantly improve 6MWT at 24 weeks
PARADIGM-HF (10)	8 442	27 months	HFrEF	NYHA II-IV,EF $\leq 40\%$	63.8 ± 11.5 vs. 63.8 ± 11.3	6 567 (78)	Enalapril	200 mg bid vs. 10 mg bid	AF: 1,517 (36.2) vs. 1,574 (37.4) VA:333 (4)	Arrhythmia: 504 (12) vs. 553 (13) AA: 285 (7) vs. 269 (6) VA: 99 (2) vs. 129 (3) cardiac arrest: 30 (0.7) vs. 56 (1.3)	SV was superior to enalapril in reducing the risks of death and of hospitalization for HFrEF
PARAGON-HF (19)	4 822	26 months	HFpEF	NYHA II-IV,EF $\ge 45\%$	72.7 ± 8.3 vs. 72.8 ± 8.5	2 317 (48)	Valsartan	200 mg bid vs. 160 mg bid	AF or AFL: 775 (32.2) vs. 777 (32.5)	Arrhythmia: 630 (26) vs. 620 (26) AA: 448 (19) vs. 409 (17) VA: 17 (0.7) vs. 10 (0.4) cardiac arrest: 17 (0.7) vs. 30 (1.2)	SV did not result in a significantly lower rate of total hospitalizations for HF and death from cardiovascular causes among patients with HFpEF
PARAMETER (27)	454	52 weeks	Hypertension	Aged ≥ 60 years with systolic hypertension	68.2 ± 5.73 vs. 67.2 ± 5.97	237 (52)	Olmesartan	200 mg bid vs. 20 mg bid		Arrhythmia: 3 (1.3) vs. 1 (0.4) AA: 2 (0.9) vs. 1 (0.4)	Demonstrated superiority of SV vs. olmesartan in reducing clinic and ambulatory central aortic and brachial pressures in elderly patients with systolic hypertension and stiff arteries

eGFR, estimated glomerular filtration rate; SCr, serum creatinine; uACR, urine albumin:creatinine ratio; BP, blood pressure; SBP, systolic blood pressure; NT-proBNP, N-terminal pro-B type natriuretic peptide; NYHA: New York Heart Association Functional Classification; LV, left ventricle; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ADHF, acute heart failure; MR, mitral regurgitation; \uparrow , increase; \downarrow , reduce; SVT, supraventricular tachycardia; AFL, atrial flutter; AF, atrial fibrillation; AA, atrial arrhythmias; 6MWT, 6-min walk distance; STEMI, ST segment elevation myocardial infarction. I^2 test, P < 0.05 was considered statistically significant. All results are in line with the declarations of PRISMA and Metaanalysis (23).

Publication Bias and Sensitivity Analysis

Publication bias was judged using funnel plot, Begg and Berlin (24), and Egger's test (25), P < 0.05 was considered statistically significant.

RESULTS

Description of Selected Studies

A total of 1, 564 possible articles or studies were initially identified, and 446 possible articles were left after filtered repeated research by endnote. The remaining articles were judged by the two researchers according to criteria, final 16 RCTs were included for analysis. The flow chart is shown in **Figure 1**.

Study Characteristics

The detailed characteristics of 16 studies (10, 19, 20, 26–38) are shown in **Table 1**. Most of the data are come from ClinicalTrials.gov, 14 trials are multi-center and 12 trials are aimed at patients with HF. The total number of subjects is 22, 563 and the follow-up ranged from 8 weeks to 33.9 months. All are RCTs.

Quality Assessment

The quality assessment for the included studies is presented in **Figures 2**, **3**. Randomization assignment was conducted using computer-generated random numbers in a majority of the trials and prespecified outcomes were reported by all trials. Individual studies did not specifically describe the methods used to hide and allocate sequences. Overall, the included studies are of high quality.

Clinical Outcomes Evaluation

The analysis results are summarized in Table 2.

The Efficacy of Sacubitril/Valsartan Compared to Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Inhibitor on Arrhythmias

Between the two groups, the results revealed that there was no difference in reduction in the risks of arrhythmias among all patients (RR 0.87, 95% CI 0.74–1.01, p = 0.07), arrhythmias among patients with non-HF (RR 0.98, 95% CI 0.17–5.46, p = 0.98), HF (RR 0.87, 95% CI 0.74–1.01, p = 0.07), HFrEF (RR 0.91, 95% CI 0.82–1.01, p = 0.09), and HF with preserved ejection fraction (HFpEF) (RR 0.69, 95% CI 0.36–1.31, p = 0.26) (**Figure 4**).

The Efficacy of Sacubitril/Valsartan Compared to Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Inhibitor on Severe Arrhythmias

Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of severe arrhythmias among patients with HFrEF (RR 0.83, 95% CI 0.73–0.95, p = 0.006), but the reductions in the risks of severe arrhythmias among all patients (RR 0.81, 95% CI 0.64–1.03, p = 0.09), severe arrhythmias among patients with non-HF (RR 0.98, 95% CI 0.17–5.46, p = 0.98), HF (RR 0.81, 95% CI 0.63–1.03, p = 0.08), and HFpEF (RR 1.10, 95% CI 0.95–1.27, p = 0.21) were no significant between-group difference (**Figure 5**).

The Efficacy of Sacubitril/Valsartan Compared to Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Inhibitor on Atrial Arrhythmias

Between the two groups, the results revealed that there was no difference in reduction in the risks of atrial arrhythmias among all patients (RR 0.98, 95% CI 0.83–1.16, p = 0.85), AF among all patients (RR 0.98, 95% CI 0.82–1.17, p = 0.82), AF among patients with non-HF (RR 1.15, 95% CI 0.22–5.94, p = 0.87), HF (RR 0.97, 95%



	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bi	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
ACTIVITY-HF 2021	٠	•	٠	•	•	٠	•
EVALUATE-HF 2019	٠	٠	٠	•	٠	٠	•
NCT01599104 2022	٠	•	۲	٠	٠	٠	•
NCT01615198 2017	٠	•	٠	•	•	•	•
NCT01785472 2019	•	•	•	•	•	•	•
OUTSTEP-HF 2021	•	•	•	•	•	٠	•
PARADIGM-HF 2014	•	•	•	•	•	•	•
PARAGON-HF 2019	٠	•	٠	•	•	•	•
PARALLAX 2021	•	•	•	•	•	•	•
PARALLEL-HF 2021	•	٠	•	•	•	٠	•
PARAMETER 2017	•	•	•	•	•	•	•
PARAMOUNT 2012	٠	٠	٠	•	٠	٠	•
PIONEER-HF 2019	٠	•	•	٠	•	٠	•
PRIME 2019	•	•	•	•	•	•	•
Wang H 2021	•	•	•	•	•	•	?
Wang Q 2022	•	•	•	•	•	•	?

FIGURE 3 | Methodological quality summary: authors' judgments about each methodological quality.

CI 0.79–1.18, p = 0.73), HFrEF (RR 1.10, 95% CI 0.93–1.29, p = 0.27), and HFpEF (RR 0.69, 95% CI 0.41–1.16, p = 0.16) (**Figure 6**).

TABLE 2 | Results of meta-analysis.

Outcomes	RR	95% CI	Р	No. of participants (trials)
Arrhythmias				
All patients	0.87	0.74–1.01	0.07	22,205 (16)
Non-HF	0.98	0.17–5.46	0.98	3,637 (4)
HF	0.87	0.74-1.01	0.07	18,568 (12)
HFrEF	0.91	0.82-1.01	0.09	11,069 (8)
HFpEF	0.69	0.36–1.31	0.26	7,361 (3)
Severe arrhythm	ias			
All patients	0.81	0.64–1.03	0.09	22,205 (16)
Non-HF	0.98	0.17–5.46	0.98	3,637 (4)
HF	0.81	0.63–1.03	0.08	18,568 (12)
HFrEF	0.83	0.73–0.95	0.006*	11,523 (9)
HFpEF	1.10	0.95–1.27	0.21	7,361 (3)
Atrial arrhythmia	1			
All patients	0.98	0.83–1.16	0.85	220,789 (13)
AF				
All patients	0.98	0.82-1.17	0.82	20,789 (13)
Non-HF	1.15	0.22–5.94	0.87	2,476 (3)
HF	0.97	0.79–1.18	0.73	18,313 (10)
HFrEF	1.10	0.93–1.29	0.27	10,814 (6)
HFpEF	0.69	0.41–1.16	0.16	7,499 (4)
VAs				
HF	0.87	0.70-1.09	0.23	15,753 (8)
HFrEF	0.82	0.64–1.03	0.09	10,932 (7)
HFpEF	1.69	0.77–3.68	0.19	4,821 (1)
VF				
HF	0.85	0.54–1.35	0.49	15,552 (7)
HFrEF	0.86	0.53–1.40	0.54	10,731 (6)
HFpEF	0.79	0.21–2.95	0.73	4,821 (1)
VT				
HF	0.76	0.58–0.99	0.04*	15,753 (8)
HFrEF	0.69	0.51–0.92	0.01*	9,716 (4)
HFpEF	2.48	0.78–7.90	0.12	4,821 (1)
Cardiac arrest				
HF	0.52	0.37-0.73	0.0002*	15,211 (5)
HFrEF	0.49	0.32-0.76	0.001*	10,390 (4)
HFpEF	0.56	0.31-1.02	0.06	4,821 (1)
Cardiac arrest o	r VF			
HF	0.63	0.48–0.83	0.001*	15,552 (7)
HFrEF	0.65	0.47-0.89	0.008*	10,731 (6)
HFpEF	0.60	0.35–1.02	0.06	4,821 (1)

*p < 0.05.

HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; AF, atrial fibrillation; VAs, ventricular arrhythmias; VF, ventricular fibrillation; VT, ventricular tachycardia; CI, confidence interval; RR, relative risk.

The Efficacy of Sacubitril/Valsartan Compared to Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Inhibitor on Ventricular Arrhythmias

All data of VAs were came from patients with HF. Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of VT among patients with HFrEF (RR 0.69, 95% CI 0.51–0.92, p = 0.01), but the reductions in the risks

Study or Subgroup	Experimental Control Events Total Events Total Weight M	Risk Ratio M-H, Random, 95% Cl	Risk Ratio M-H, Random, 95% Cl	Risk of Bias A B C D E F G
1.1.1 Arrhythmias ACTIVITY-HF 2021	5 103 4 98 0.3%	1.19 [0.33, 4.30]		
EVALUATE-HF 2019	5 231 0 233 0.1%	11.09 [0.62, 199.50]	→	
NC101599104 2022 NCT01615198 2017	2 296 0 292 0.1%	4.93 [0.24, 102,30]	· •	
NCT01785472 2019	0 950 1 484 0.1%	0.17 [0.01, 4.17]		
OUTSTEP-HF 2021 PARADIGM-HF 2014	18 309 19 310 1.2% 504 4203 553 4229 12.7%	0.95 [0.51, 1.78] 0.92 [0.82, 1.03]	-	
PARAGON-HF 2019	630 2419 620 2402 14.0%	1.01 [0.92, 1.11]	+	
PARALLAX 2021 PARALLEL-HE 2021	10 1118 15 1121 0.8% 11 111 12 112 0.8%	0.67 [0.30, 1.48]		
PARAMETER 2017	3 229 1 225 0.1%	2.95 [0.31, 28.13]		
PARAMOUNT 2012	5 149 16 152 0.5%	0.32 [0.12, 0.85]		
PRIME 2019	0 60 1 58 0.1%	0.32 [0.01, 7.76]		
Wang H 2021	6 68 9 69 0.5%	0.68 [0.25, 1.80]		
Subtotal (95% CI)	11526 10679 34.0%	0.87 [0.74, 1.01]	•	
Total events Heterogeneity: Tau² Test for overall effec	1227 1301 = 0.02; Chi² = 21.93, df = 15 (P = 0.11); l² = 32% : Z = 1.78 (P = 0.07)			
1.1.2 Non-HF with a	rhythmias			
NCT01599104 2022 NCT01615198 2017	2 296 0 292 0.1%	0.17 [0.01, 4.12]		
NCT01785472 2019	0 950 1 484 0.1%	0.17 [0.01, 4.17]		
PARAMETER 2017 Subtotal (95% CI)	3 229 1 225 0.1%	2.95 [0.31, 28.13]		
Total events	5 3	0.50 [0.17, 5.40]		
Heterogeneity: Tau ² Test for overall effec	= 0.94; Chi ² = 4.31, df = 3 (P = 0.23); l ² = 30% I: Z = 0.03 (P = 0.98)			
1.1.3 HF with arrhytl	imias	1 10 0 22 4 201		******
EVALUATE-HF 2021	5 231 0 233 0.1%	11.09 [0.62, 199.50]		
OUTSTEP-HF 2021	18 309 19 310 1.2%	0.95 [0.51, 1.78]	+	
PARADIGM-HF 2014 PARAGON-HF 2019	630 2419 620 2402 14.0%	0.92 [0.82, 1.03] 1.01 [0.92, 1.11]	1	
PARALLAX 2021	10 1118 15 1121 0.8%	0.67 [0.30, 1.48]		
PARALLEL-HF 2021 PARAMOUNT 2012	11 111 12 112 0.8% 5 149 16 152 0.5%	0.92 [0.43, 2.01] 0.32 [0.12, 0.85]		
PIONEER-HF 2019	13 439 20 436 1.0%	0.65 [0.33, 1.28]		
PRIME 2019 Wang H 2021	0 60 1 58 0.1%	0.32 [0.01, 7.76]		
Wang Q 2022	15 69 29 69 1.7%	0.52 [0.31, 0.88]		
Subtotal (95% CI)	9279 9289 33.7%	0.87 [0.74, 1.01]	•	
Heterogeneity: Tau ² Test for overall effec	= 0.02; Chi ² = 17.59, df = 11 (P = 0.09); l ² = 37% : Z = 1.80 (P = 0.07)			
1.1.4 HFrEF with arr	nythmias			
ACTIVITY-HF 2021	5 103 4 98 0.3%	1.19 [0.33, 4.30]		
OUTSTEP-HF 2019	5 231 U 233 U.1% 18 309 19 310 1.2%	0.95 [0.51, 1.78]		
PARADIGM-HF 2014	504 4203 553 4229 12.7%	0.92 [0.82, 1.03]	1	
PARALLEL-HF 2021 PIONEER-HF 2019	11 111 12 112 U.8% 13 439 20 436 1.0%	0.92 [0.43, 2.01] 0.65 [0.33, 1.28]		
PRIME 2019	0 60 1 58 0.1%	0.32 [0.01, 7.76]		
Wang H 2021 Subtotal (95% CI)	6 68 9 69 0.5% 5524 5545 16.8%	0.68 (0.25, 1.80) 0.91 (0.82, 1.01)	•	
Total events	562 618	,,		
Heterogeneity: Tau ^a Test for overall effec	= 0.00; Chi² = 4.81, df = 7 (P = 0.68); l² = 0% : Z = 1.71 (P = 0.09)			
1.1.5 HFpEF with arr PARAGON-HE 2019	hythmias 630 2419 620 2402 14.0%	1.01 [0.92 1.11]	Ļ	******
PARALLAX 2021	10 1118 15 1121 0.8%	0.67 [0.30, 1.48]		
PARAMOUNT 2012 Subtotal (95% CD	5 149 16 152 0.5% 3686 3675 15.3%	0.32 [0.12, 0.85]		
Total events	645 651	0.00 [0.00, 1.01]	•	
Heterogeneity: Tau² Test for overall effec	= 0.22; Chi ² = 6.27, df = 2 (P = 0.04); i ² = 68% : Z = 1.14 (P = 0.26)			
Total (95% CI)	32262 30578 100.0%	0.91 [0.84, 0.97]	•	
i otai events Heterogeneitv: Tau²	3001 3871 = 0.01; Chi ² = 56.39, df = 42 (P = 0.07); l ² = 26%	-		
Test for overall effec	Z = 2.67 (P = 0.008)	0.02 Favours	0.1 1 10 50 (experimental) Favours (control)	
Test for subgroup di	fferences: Chi ² = 0.99, df = 4 (P = 0.91), l ² = 0%		, , ,	
(A) Random sequer	ce generation (selection bias)			
(B) Allocation conce	alment (selection bias)			
(C) Blinding of partic (D) Blinding of outco	ipanis and personnei (performance blas) me assessment (detection blas)			
(E) Incomplete outco	me data (attrition bias)			
(F) Selective reportin (G) Other bias	g (reporting blas)			
E 4 The efficacy of SV compared to	ACEI/ARB on arrhythmias.			

of VA among patients with HF (RR 0.87, 95% CI 0.70–1.09, p = 0.23), VA among patients with HFrEF (RR 0.82, 95% CI 0.64–1.03, p = 0.09), VA among patients with HFpEF (RR 1.69, 95% CI 0.77–3.68, p = 0.19), VF among patients with HF (RR 0.85, 95% CI 0.54–1.35, p = 0.49), VF among patients with HFrEF (RR 0.86, 95% CI 0.53–1.40, p = 0.54), VF among patients with HFrEF (RR 0.86, 95% CI 0.21–2.95, p = 0.73), and VT among patients with HFpEF (RR 2.48, 95% CI 0.78–7.90, p = 0.12) were no significant between-group difference (**Figure 7**).

The Efficacy of Sacubitril/Valsartan Compared to Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Inhibitor on Cardiac Arrest or Cardiac Arrest Combined With Ventricular Fibrillation

Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of cardiac arrest among patients with HF (RR 0.52, 95% CI 0.37–0.73, p = 0.0002), cardiac arrest among patients with HFrEF (RR 0.49, 95% CI 0.32–0.76, p = 0.001), cardiac arrest or VF among



patients with HF (RR 0.63, 95% CI 0.48–0.83, p = 0.001), and cardiac arrest or VF among patients with HFrEF (RR 0.65, 95% CI 0.47–0.89, p = 0.008), but the reductions in the risks of cardiac arrest among patients with HFpEF (RR 0.56, 95% CI 0.31–1.02, p = 0.06) and cardiac arrest or VF among patients with HFpEF (RR 0.60, 95% CI 0.35–1.02, p = 0.06) were no significant between-group difference (**Figure 8**).

Sensitivity Analysis and Publication Bias

Any single study excluded would not affected the significance of our combined effect size for either outcome by sensitivity analysis (**Figure 9**). No obvious publication bias was found in the visual inspection of funnel plots (**Figure 10**), Egger's test (**Figure 11**) for OS with a *p*-value of 0.225 and Begg's Test (**Figure 12**) for OS with a *p*-value of 0.822 also proved it. Therefore, we could conclude that all the included studies have no obvious publication bias and the result is stable.

DISCUSSION

Major Findings

Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of severe arrhythmias, VT and cardiac arrest among patients with HFrEF, and cardiac arrest among patients with HF by 17, 31, 51, and 48%, respectively, and the reductions in the risks of arrhythmias, severe arrhythmias, atrial arrhythmias, AF and VAs among patients with HF were 13, 19, 22, and 13%, respectively with no significant betweengroup difference. Although the specific relationship between the data of cardiac arrest and VF in this meta-analysis cannot be determined, considering that the main cause of cardiac arrest is VF, we combined the data for statistical analysis, and the results revealed that SV therapy did significantly reduce in reducing the risks of cardiac arrest or VF among patients with HF, HFrEF by 37 and 35%, respectively compared with ACEI/ARB therapy. Therefore, we consider that SV therapy did significantly reduce in the risks of cardiac arrest in patients with HF, mainly HFrEF, compared with ACEI/ARB therapy. Similarly, we can speculate about the superior role of SV therapy in reducing the use of implantable cardioverter-defibrillator from SV therapy led to a reduction in the risks of VT, VF, and cardiac arrest or VF compared with ACEI/ARB therapy in HFrEF. Further research is needed to confirm these speculations. Overall, the results of our meta-analysis revealed that SV therapy in specific groups are effective and provided superior arrhythmias reduction than ACEI/ARB therapy.

Mechanisms

Cardiovascular disease mainly leads to the activation of the neuroendocrine system, including sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAAS), and vasoactive peptides (mainly natriuretic peptides) (40). Despite the initial functional response, chronic SNS and RAAS activation increases cardiac afterload, which increasing myocardial oxygen consumption and leading to deleterious proliferative remodeling effects (41). Natriuretic peptide system (NPs) mediates the activation of cyclic guanosine monophosphatedependent signaling pathways through corresponding receptors, resulting in vasodilation, natriuretic diuresis, and lowering of blood pressure (40). In addition, cardiac filling, preload, and ventricular remodeling are reduced by NPs and corresponding receptors through inhibiting endothelin secretion, and activation of RAAS and SNS. The effect of SV is mainly considered to enhance NPs and inhibit RAAS by inhibiting neprilysin, moreover, it has more effective dual inhibitory effect on the neuroendocrine system by combining with ARB. Furthermore, enhancing the NPs has favorable cardiovascular effects in HF and is an ideal complementary therapeutic target for RAAS and SNS blockade. Enkephalinase inhibitor (NEPI) in SV exerts natriuretic diuresis, dilates blood vessels, and reduces blood pressure by upregulating the levels of NPs, bradykinin, and adrenomedullin. Also, inhibition of sympathetic tone and RAAS can reduce aldosterone, myocardial fibrosis and hypertrophy, and ventricular remodeling. In addition to counteracting the

_Study	Exp or Subgroup Eve	oerimental ents Total	Contr Events	ol Total W	eight M	Risk Ratio -H, Random, 95% Cl	N	Risk Ratio 1-H, Random, 95% Cl	Risk of Bias A B C D E F G
3.1.1 A ACTIVI	Atrial arrhythmia /ITY-HF 2021	2 103	3	98	0.2%	0.63 [0.11, 3.72]			
EVALU NCT01	UATE-HF 2019 01615198 2017	2 231 1 296	0	233 292	0.1% 0.1%	5.04 [0.24, 104.48] 2.96 [0.12, 72.36]	. —		
NCT01 OUTS1	01785472 2019 STEP-HF 2021	0 950 8 309	1 6	484 310	0.1% 0.5%	0.17 [0.01, 4.17] 1.34 [0.47, 3.81]	•		
PARAG	DIGM-HF 2014 GON-HF 2019	285 4203 448 2419	269 409	4229 2402 1	9.5% 1.8%	1.07 [0.91, 1.25] 1.09 [0.96, 1.23]		†	
PARAL	ALLAX 2021	10 1118	15	1121	0.8%	0.67 [0.30, 1.48]	_		
PARAL	METER 2017	2 229	4	225	0.3%	1.97 [0.18, 21.52]	_		
PARAM	MOUNT 2012 EER-HF 2019	3 149 6 439	9	152 436	0.3% 0.3%	0.34 [0.09, 1.23] 1.49 [0.42, 5.24]			
Wang Subtot	a Q 2022 Stal (95% CI)	15 69 10626	29	69 10163 2	1.8% 5.8%	0.52 [0.31, 0.88] 0.98 [0.83, 1.16]			
Total e	events	786	750	- 0.000 18	- 24.04				
Test fo	for overall effect: Z = 0.	19 (P = 0.85)	ui = 12 (P	= 0.23), 1-	= 21%				
3.1.2 A ACTIVI	AF /ITY-HF 2021	2 103	1	98	0.1%	1.90 [0.18, 20.65]			
EVALU NCT01	UATE-HF 2019	2 231	0	233	0.1%	5.04 [0.24, 104.48]			· • • • • • • • • • • • • • • • • • • •
NCT01	01785472 2019	0 950	1	484	0.1%	0.17 [0.01, 4.17]	←		
OUTS1 PARAD	STEP-HF 2021 DIGM-HF 2014	8 309 267 4203	4 250	310 4229	0.4% 9.2%	2.01 [0.61, 6.59]		+	
PARAG	GON-HF 2019	410 2419	384	2402 1	1.5%	1.06 [0.93, 1.20]			
PARAL	ALLEL-HF 2021	4 111	4	112	0.8%	1.01 [0.26, 3.93]	-		******
PARAN	METER 2017 MOUNT 2012	2 229	1 9	225 152	0.1% 0.3%	1.97 [0.18, 21.52]			
PIONE	EER-HF 2019	4 439	3	436	0.2%	1.32 [0.30, 5.88]			
Subtot	otal (95% CI)	10626	29	10163 2	4.8%	0.98 [0.82, 1.17]		•	
Total e Hetero	events rogeneity: Tau ² = 0.02:	728 Chi ² = 15 54	701 df = 12 (P	= 0.21); P	= 23%				
Test fo	for overall effect: Z = 0.	23 (P = 0.82)		0.2.7,1					
3.1.3 N NCT01	Non-HF with AF 01615198 2017	1 296	0	292	0.1%	2.96 [0.12, 72.36]			
NCT01 PARAN	01785472 2019 METER 2017	0 950	1	484 225	0.1% 0.1%	0.17 [0.01, 4.17]	·		
Subtot	otal (95% CI)	1475		1001	0.2%	1.15 [0.22, 5.94]			
i otal e Hetero	events rogeneity: Tau² = 0.00;	3 Chi ² = 1.90, i	2 1f = 2 (P =	0.39); I² = 0	1%				
Test fo	for overall effect: Z = 0.	16 (P = 0.87)							
3.1.4 H	HF with AF	2 103	1	98	0.1%	1 90 10 18 20 651			
EVALU	UATE-HF 2019	2 231	ò	233	0.1%	5.04 [0.24, 104.48]	-		
OUTS1 PARAD	STEP-HF 2021 DIGM-HF 2014	8 309 267 4203	4 250	310 4229	0.4% 9.2%	2.01 [0.61, 6.59]		-	
PARAG	GON-HF 2019	410 2419	384	2402 1	1.5%	1.06 [0.93, 1.20]			
PARAL	ALLEL-HF 2021	4 111	4	1121	0.8%	1.01 [0.26, 3.93]	-		
PARAN PIONE	MOUNT 2012 EER-HF 2019	3 149 4 439	9 3	152 436	0.3% 0.2%	0.34 [0.09, 1.23] 1.32 [0.30, 5.88]		<u> </u>	
Wang	Q 2022	15 69	29	69	1.8%	0.52 [0.31, 0.88]			
Total e	events	725	699	9102 2	4.070	0.97 [0.79, 1.16]		Ĩ	
Hetero Test fo	rogeneity: Tau ² = 0.02; for overall effect: Z = 0.	Chi ² = 13.63 34 (P = 0.73)	df= 9 (P =	= 0.14); I ² =	34%				
3.1.5 H ACTIVI	HFrEF with AF	2 103	1	98	0.1%	1 90 10 18 20 651	-		
EVALU	UATE-HF 2019	2 231	Ó	233	0.1%	5.04 [0.24, 104.48]	_		
PARAE	DIGM-HF 2021	8 309 267 4203	4 250	4229	0.4% 9.2%	1.07 [0.91, 1.27]		+	
PARAL	LLEL-HF 2021 EER-HF 2019	4 111 4 439	4	112 436	0.3% 0.2%	1.01 [0.26, 3.93]	-		
Subtot	otal (95% CI)	5396		5418 1	0.2%	1.10 [0.93, 1.29]		•	
Total e Hetero	events rogeneity: Tau² = 0.00;	287 Chi² = 2.30,	262 1f = 5 (P =	0.81); I² = 0	1%				
Test fo	for overall effect: Z = 1.	11 (P = 0.27)							
3.1.6 H PARAG	GON-HF 2019	410 2419	384	2402 1	1.5%	1.06 [0.93, 1.20]		+	
PARAL	LLAX 2021 MOUNT 2012	10 1118	15 9	1121 152	0.8% 0.3%	0.67 [0.30, 1.48]			
Wang	Q 2022	15 69	29	69	1.8%	0.52 [0.31, 0.88]			•••••
Subtot Total e	events	3755 438	437	3/44 1	4.4%	0.09 [0.41, 1.16]			
Hetero Test fo	rogeneity: Tau ² = 0.18; for overall effect: Z = 1.	Chi ² = 10.52 40 (P = 0.16)	df= 3 (P =	: 0.01); I² =	71%				
Total (Total e	(95% CI) events 2	41029 967	2851	39651 10	0.0%	1.00 [0.93, 1.08]		•	
Hetero	rogeneity: Tau ² = 0.01;	Chi ² = 59.99	df= 48 (P	= 0.11); l²	= 20%		0.1 0.2	0.5 1 2 5 10	
Test fo Test fo	ior overall effect: Z = 0. for subgroup differenc	o∠ (P = 0.99) es: Chi² = 3.4	3, df = 5 (F	P = 0.63), I ²	= 0%	F	avours (expe	erimental] Favours (control)	
Risk of	of bias legend	aration (est-	ction his-						
(A) Rai (B) Allo	anuom sequence gen location concealment	eration (sele (selection bi	cuon bias) as)						
(C) Blir (D) Blir	linding of participants linding of outcome as	and personn sessment (de	el (perform etection bis	iance bias) as)					
(E) Inc	complete outcome da	a (attrition bi	as)						
(F) Sel (G) Oth	ther bias	rany plas)							
URE 6 The efficacy of SV com	npared to ACE	EI/ARB c	n atria	arrhyt	hmias	S.			

vasoconstriction problem caused by the increased concentration of angiotensin II caused by NEPI, the combined use of valsartan can enhance the inhibition of vasoconstriction, cardiomyocyte proliferation and fibrosis, and myocardial remodeling by further inhibit SNS and decreases aldosterone levels by inhibiting sustained activation of RAAS (42, 43).

udy or Subgroup	Experim	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl	ABCDEFG
TIVITY-HF 2021	2	103	0	98	0.1%	4.76 [0.23. 97.91]		
ALUATE-HF 2019	2	231	0	233	0.1%	5.04 [0.24, 104.48]		
JTSTEP-HF 2021	5	309	2	310	0.3%	2.51 [0.49, 12.83]		
RADIGM-HF 2014	99	4203	129	4229	20.4%	0.77 [0.60, 1.00]	1	
RALLEL-HF 2021	7	111	8	112	1.3%	0.88 [0.33, 2.35]		
ONEER-HF 2019	5	439	8	436	1.3%	0.62 [0.20, 1.88]		
RIME 2019	0	60	1	58	0.2%	0.32 [0.01, 7.76]		
btotal (95% CI)	4.07	7875	450	7878	25.3%	0.87 [0.70, 1.09]	٩	
terogeneity: Chi ² = 8 st for overall effect 3	3.45, df = 7	(P = 0.2	9); I ² = 17	%				
2 HFrEF with VA	- 1.20 (P	= 0.23)						
TIVITY-HF 2021	2	103	0	98	0.1%	4.76 [0.23, 97.91]		
ALUATE-HF 2019	2	231	0	233	0.1%	5.04 [0.24, 104.48]		
RADIGM-HF 2014	99	4203	129	4229	20.4%	0.77 [0.60, 1.00]	-	
RALLEL-HF 2021	7	111	8	112	1.3%	0.88 [0.33, 2.35]		
DNEER-HF 2019	5	439	8	436	1.3%	0.62 [0.20, 1.88]		
IME 2019	0	60	1	58	0.2%	0.32 [0.01, 7.76]		
tal events	120	5450	148	5476	23.1%	0.82 [0.64, 1.03]	1	
terogeneity: Chi ² = 5 st for overall effect 2	5.27, df = 6 Z = 1.68 (P	(P = 0.5 = 0.09)	1); I ² = 09	6				
1.3 HFpEF with VA								
RAGON-HF 2019	17	2419	10	2402	1.6%	1.69 [0.77, 3.68]	<u> </u>	
protal (95% CI)	17	2419	10	2402	1.6%	1.69 [0.77, 3.68]		
terogeneity: Not app	olicable	= 0.10	10					
.4 HF with VF	. = 1.32 (P	- 0.13)						
ALUATE-HF 2019	1	231	0	233	0.1%	3.03 [0.12, 73.90]		
RADIGM-HE 2021	2	309	28	310	U.1%	5.02 [U.24, 104.06] 0.70 ID 45 1 201	-	
RAGON-HF 2014	4	2419	20	2402	4.470	0.79 [0.45, 1.38]		0000000
RALLEL-HF 2021	3	111	4	112	0.6%	0.76 [0.17, 3.30]		
DNEER-HF 2019	0	439	0	436		Not estimable		
IME 2019 htotal (95% Ch	0	60 7772	1	58 7790	0.2% 6 %	0.32 [0.01, 7.76]	•	
tal events	32	2	38	1100	0.5%	0.00 [0.04, 1.35]		
terogeneity: Chi ^a = 2 st for overall effect: 2	2.38, df = 5 Z = 0.69 (P	(P = 0.7 = 0.49)	9); I ² = 09	6				
.5 HFrEF with VF				00-				
ALUATE-HF 2019	1	231	0	233	0.1%	3.03 [0.12, 73.90]		
RADIGM-HF 2021	22	4203	28	4229	4 4 %	0.79 [0.45 1.38]		0000000
RALLEL-HF 2021	3	111	4	112	0.6%	0.76 [0.17, 3.30]		
DNEER-HF 2019	0	439	0	436		Not estimable		
ME 2019	0	60	1	58	0.2%	0.32 [0.01, 7.76]		
prordl (95% CI) tal events	20	5353	22	5378	5.5%	0.86 [0.53, 1.40]	T	
terogeneity: Chi ^a = 2	2.38, df = 4	(P = 0.6	7); I² = 09	6				
1.6 HEnEE with V	. = u.61 (P	- U.54)						
ARAGON-HF 2019	4	2419	5	2402	0.8%	0.79 [0.21, 2.95]		
ubtotal (95% CI)		2419		2402	0.8%	0.79 [0.21, 2.95]	-	
atai events eterogeneity: Not app	4 olicable		5					
est for overall effect.	Z = 0.34 (P	= 0.73)						
1.7 HF with VT TIVITY-HF 2021	2	103	p	9.9	0.1%	4 76 ID 23 97 911		
ALUATE-HF 2019	1	231	0	233	0.1%	3.03 [0.12, 73.90]		0000000
JTSTEP-HF 2021	3	309	1	310	0.2%	3.01 [0.31, 28.78]		
RADIGM-HF 2014	66	4203	105	4229	16.6%	0.63 [0.47, 0.86]	-	
RAGON-HF 2019	10	2419	4	2402	0.6%	2.48 [0.78, 7.90]		
RALLEL-HF 2021	4	111	4	112	0.6%	1.01 [0.26, 3.93]		
IME 2019	0	438 60	ń	- 58	1.170	Not estimable		0000000
btotal (95% CI)	5	7875	5	7878	19.3%	0.76 [0.58, 0.99]	•	
al events	91		121	N.				
terogeneity: Chi ^a = 9 st for overall effect: 2	8.14, df = 6 Z = 2.03 (P	(P = 0.1 = 0.04)	(); I² = 34	196				
.8 HFrEF with VT						1 80 10 /		
RADIGM-HF 2014	2	103	0	98	0.1%	4.76 [0.23, 97.91]		
NEER-HF 2021	3	309	1	233	0.1%	3.01 [0.31, 28 78]		0000000
IME 2019	66	4203	105	4229	16.6%	0.63 [0.47, 0.86]	+	
ototal (95% CI)		4846		4870	16.9%	0.69 [0.51, 0.92]	•	
ar events terogeneity: Chi ^a = 4	72 1.32, df = 3	(P = 0.2	106 3); I ² = 31	%				
9 HEnEE with V/	2.51 (P	- 0.01)						
RAGON-HF 2019	10	2419	4	2402	0.6%	2.48 [0.78, 7.90]		
btotal (95% CI)		2419		2402	0.6%	2.48 [0.78, 7.90]	-	
tal events	10		4					
erogeneity: Not app st for overall effect: 2	mcaple Z = 1.54 (P	= 0.12)						
al (95% Cl)		46434		46466	100.0%	0.83 [0.74, 0.93]	•	
tal events	511		623					
terogeneity: Chi ^a = 4	11.16, df =	39 (P = 0	1.38); l ^a =	5%			0.01 0.1 1 10 100	
ist for subgroup diffect.2	= 3.27 (P	= 0.001) hi ² = 9.01	df= 9 4	P = 0.34	1 12 10	F F	avours (experimental) Favours (control)	
sk of bias legend		= 0.31	, ui = 0 (i	- 0.00	, i = 10.			
) Random sequence	e generatio	n (selec	tion bias)				
) Allocation concealr	ment (sele	ction bia	s)					
) Blinding of particip	ants and p	ersonne	l (perforn	nance bi	ias)			
	e assessr	nent (def	ection bi	as)				
Blinding of outcom	ie data (att	ndon bia	s/					
Blinding of outcom Incomplete outcom	(reporting	DI3C)						
Blinding of outcom Incomplete outcom Selective reporting Other bias	(reporting	olas)						

The mechanism of SV improving arrhythmia is not clear, which may be related to the treatment with SV provided superior cardiac remodeling (including structure and electrophysiology) and fibrosis (44) reduction than angiotensin inhibition, as cardiac remodeling can lead to increased susceptibility to arrhythmia and fibrosis, a well-recognized factor for malignant VA, is an important basis of cardiac remodelling (45, 46). Besides, NPs regulation has affect on myocardial electrophysiological properties and anatomical substrate, which are major factors for the development of sustained VA. The inhibition of SV on SNS and RAAS may exert a direct effect on reducing the risk of arrhythmia in HF. SNS and RAAS are activated and the secretion of neurohormone is increased in HF, lead to arrhythmia by increasing myocardial automaticity, altering conductivity and refractory periods, constricting of blood vessels to alter cardiac load, and promoting ventricular remodeling together (47, 48). In pre-clinical studies, SV improved the risk of persistent VA by reducing wall stress (49) and the activity of membrane ion channels, such as sodium channel NaV1.5 protein and potassium channel proteins, associated with VT/VF, which decrease trigger factors and perpetuating/maintaining the event of Vas (50). Moreover, demonstrated superiority of SV vs. ACEI/ARB in reducing VAs though improving potential systolic and diastolic function, calcium homeostasis and conduction delay, increased pacing threshold to induce arrhythmia, a decrease of action potential duration (APD) and the maximum slope of APD restitution by inhibiting the CaMK II pathway, and down-regulation of small-conductance Ca²⁺activated potassium channel type 2 (44, 51, 52).

Findings Relevant to Other Studies

The post hoc study of PARADIGM-HF revealed that, compared with enalapril therapy, SV therapy did significantly reduce in reducing the risk of ventricular arrhythmia and the composite arrhythmia outcome in HFrEF (14). A retrospective analysis of 1-year telemonitoring in 151 SV-treated HFrEF patients with implantable cardioverter-defibrillator/cardiacresynchronization-therapy (18) revealed that SV treatment resulted in a reduction in mean VT/VF burden, non-sustained VT and treatments, which were associated with improved biventricular pacing and a higher degree of reverse remodeling. These results are consistent with our findings that SV therapy led to a greater reduction in the risks of VT/VF compared with ACEI/ARB therapy in HFrEF. The results of the PARADIGM-HF (9) revealed that SV had a direct effect on reducing the risk of SCD compared with enalapril, which is consistent with the findings of our study that SV therapy reduced the risk of cardiac arrest in HFrEF by 51% compared with ACEI/ARB therapy. SV therapy did not affect AF burden in the study of Martens (18), and the same is true of our study. Other than these, SV therapy could reduce the risk of severe arrhythmias by 17% in HFrEF compared with ACEI/ARB therapy. Above results are consistent with consistent with our findings, confirming the reliability of our results.

Thoughts on Difference of Therapy Effect

Our study finds that SV therapy is superior in reducing the risk of certain arrhythmias merely in HFrEF compared with ACEI/ARB therapy, which may be related to the different therapeutic effects of SV in different EF spectra (53, 54). Although has been recommended for the treatment of HFpEF by guidelines, SV merely has a significant therapeutic advantage in morbidity among patients with HFrEF, which could be found in other large clinical trials, due to multi-factors. The pathophysiological heterogeneity within the broader clinical spectrum of HFpEF, which may represent a different progression or disease, lead to the effect of neurohormone antagonists on HFpEF is relatively weak compared with HFrEF (55). Moreover,

	- ·		0.1			D:-1 D-4:-	Dial Datio	Dist. (Diss
Study or Subgroup	Experim	Total	Events	Total	Weight	RISK Ratio M.H. Fixed, 95% C	RISK RATIO M.H. Fixed, 95% Cl	RISK OT BIAS
5.1.1 HF with cardiac a	arrest	Total	Lucino	Total	Treight	III-11,11ACU, 00/0 C		<u>NDODLIO</u>
EVALUATE-HF 2019	0	231	0	233		Not estimable		
OUTSTEP-HF 2021	0	309	2	310	0.6%	0.20 (0.01, 4.16	· · · · · · · · · · · · · · · · · · ·	
PARADIGM-HF 2014	30	4203	56	4229	12.5%	0.54 (0.35, 0.84	·	
PARAGON-HF 2019	17	2419	30	2402	6.7%	0.56 [0.31, 1.02]		
PIONEER-HF 2019	0	439	4	436	1.0%	0.11 [0.01, 2.04	·	
Subtotal (95% CI)		7601		7610	20.8%	0.52 [0.37, 0.73]	◆	
Total events	47		92					
Heterogeneity: Chi ² = 1	.56, df = 3) (P = 0.6	7); I ² = 09	6				
Test for overall effect: 2	Z = 3.73 (P	= 0.0003	2)					
5 1 2 HErEE with cardi	ac arrest							
EVALUATE UE 2010		221	0	222		Not estimable	.	******
	0	200	2	233	20.0	0.2010.01 / 16	• • • • • • • • • • • • • • • • • • •	
PARADIGM-HE 2014	30	4203	56	4220	12.5%	0.54 (0.35, 0.84)		
PIONEER-HE 2019	0	4203	4	4223	1 0%	0.11 [0.01 2.04]	· •	
Subtotal (95% CI)		5182	4	5208	14.0%	0.49 [0.32, 0.76]	•	
Total events	30	5102	62	5200	14.070	0.45 [0.52, 0.10]	· · · ·	
Heterogeneity: Chi ² = 1	50 df= 2	(P = 0.4	7): I ² = 09	6				
Test for overall effect: 2	Z = 3.22 (P	= 0.001)	.,,	•				
5.1.3 HEPEF with cardi	ac arrest	2440		2402	0.70	0.50 10.04 4.00		
PARAGON-HE 2019 Subtatal (05%, CD	17	2419	30	2402	6.7%	0.56 [0.31, 1.02		
Subtotal (95% CI)	47	2419	~~	2402	0.7%	0.56 [0.51, 1.02]	\bullet	
l otal events	17		30					
Heterogeneity: Not app Test for overall effect: 7) IICable 7 – 1 00 /P	(90.0						
Testion overall effect. 2	- 1.30 (i	- 0.00)						
5.1.4 HF with cardiac a	arrest or \	/F						
EVALUATE-HF 2019	1	231	0	233	0.1%	3.03 [0.12, 73.90]		
OUTSTEP-HF 2021	2	309	2	310	0.4%	1.00 [0.14, 7.08		
PARADIGM-HF 2014	52	4203	84	4229	18.7%	0.62 [0.44, 0.88]		
PARAGON-HF 2019	21	2419	35	2402	7.8%	0.60 [0.35, 1.02]		
PARALLEL-HF 2021	3	111	4	112	0.9%	0.76 [0.17, 3.30]	i <u> </u>	
PIONEER-HF 2019	3	439	4	436	0.9%	0.74 [0.17, 3.31]	i <u> </u>	
PRIME 2019	0	60	1	58	0.3%	0.32 (0.01, 7.76	·	
Subtotal (95% CI)		7772		7780	29.2%	0.63 [0.48, 0.83]	♦	
Total events	82		130			,		
Heterogeneity: Chi ² = 1	.47, df = 6	6 (P = 0.9	6); I ² = 09	6				
restion overall ellect. 2	5.20 (i	- 0.001)						
5.1.5 HFrEF with cardia	ac arrest	or VF						
EVALUATE-HF 2019	1	231	0	233	0.1%	3.03 (0.12, 73.90)		
OUTSTEP-HF 2021	2	309	2	310	0.4%	1.00 [0.14, 7.08]		
PARADIGM-HF 2014	52	4203	84	4229	18.7%	0.62 [0.44, 0.88]		
PARALLEL-HF 2021	3	111	4	112	0.9%	0.76 [0.17, 3.30]		
PIONEER-HF 2019	3	439	4	436	0.9%	0.74 [0.17, 3.31]		
PRIME 2019	0	60	1	58	0.3%	0.32 [0.01, 7.76]		
Subtotal (95% CI)		5353		5378	21.4%	0.65 [0.47, 0.89]	•	
Total events	61		95					
Heterogeneity: Chi ² = 1	.40, df = 5	6 (P = 0.9	2); I² = 09	6				
Test for overall effect: 2	Z = 2.67 (P	= 0.008)						
5.1.6 HEpEE with cardi	ac arrest	or VF						
PARAGON-HE 2019	21	2419	35	2402	78%	0.60 (0.35, 1.02)	·	
Subtotal (95% CI)	21	2419		2402	7.8%	0.60 [0.35, 1.02]	•	
Total events	21	2110	35	2102		0.000 [0.000, 1.02]	-	
Heterogeneity: Not and	licable							
Test for overall effect: 2	Z = 1.89 (P	= 0.06)						
T-4-1/05// 01		00710		20705	100.00	0.0010.00.0		
Total (95% CI)	250	30746	,	30780	100.0%	0.59 [0.50, 0.68]	▼	
Lotar events	258 256 df = 2	1 /0 - 4	444	104				
Test for overall officet 3	.35, ut = 2 7 = 6 02 /0	(C = 1.	50), P= U 11)	0.70			0.01 0.1 1 10 100	
Test for outparsus diffe	- 0.92 (P	~ 0.0000	5 df - E //	0 - 0 07	18-00		Favours [experimental] Favours [control]	
rescior subgroup diffe	rences: C	nr=1.86), ui = 5 (l	- = 0.8/	7,1=0%			
Risk of bias legend								
(A) Random sequence	e generatio	on (selec	tion bias))				
(B) Allocation concealr	nent (sele	ction bia	S)					
(C) Blinding of participa	ants and p	ersonne	l (perforn	nance b	ias)			
(D) Blinding of outcom	e assessr	ment (de	tection bi	as)				
(E) Incomplete outcom	e data (att	trition bia	s)					
(F) Selective reporting	(reporting	bias)						
(G) Other bias								
	0.0000	d to AC			100	t or Correllate an	t combined \/F	
LOI THE ENCACY OF SV	compare	ια ιο ΑΟ	⊏I/AKB (Jri∪aro	uac arres	si or Gardiac arres	L COMUNICIEU VE.	





there is a significant correlation between the degree of systolic dysfunction and frequency of arrhythmias, mainly VAs, in HFrEF, and improvement in LVEF was associated with a significant reduction in VAs and mortality (56–58). However, as normal EF of HF, HFpEF may not have a similar phenomenon. Interestingly, arrhythmias mainly existed among patients with HF in trials included, of which atrial arrhythmias are more common than VAs, and VAs mainly came from patients with HFrEF, while atrial arrhythmias mainly came from patients with HFpEF.

From the phenomena, we could speculate that HFrEF is mainly related to ventricular remodeling, while HFpEF related to atrial remodeling, and SV therapy is more advantageous in improving ventricular remodeling. Besides, differences in atrial fibrillation prevalence at baseline may have contributed to this result. Above may be the major reasons of inconsistent results in our study. Besides, the different levels of indexes of echocardiography at baseline also lead to different results of arrhythmias, such as left atrial strain and atrial volume





are associated with AF (59), global longitudinal strain and mechanical dispersion are associated with VAs, etc. It is difficult to analyze the relation between indexes of echocardiography at baseline and results of arrhythmias in our study, because only EVALUATE-HF, PRIME, and Wang H provide the data of echocardiography, while few participants and inconsistent indexes are included in the trials.

Strength and Limitations

We conducted a reasonable search of the literature and carefully screened it using strict standards, and the study included a large sample size. This is a more comprehensive analysis of the effect of SV in reducing the risk of arrhythmia, which only includes RCTs. Most of the studies in this analysis are large multicenter clinical trials, so the quality of our meta-analysis is very high. Our study confirms the advantage of SV in reducing VT, VF and cardiac arrest. However, several possible deficiencies should be noted: arrhythmias were not the main objective of these trials, the observation period of individual studies were short, most studies did not mention the occurrence of arrhythmias at baseline, only 4 trials on patients with non-HF, and the types of diseases targeted are limited. In addition, another large clinical study PARADISE-MI (ClinicalTrials.gov ID: NCT02924727) cannot be included for its data on arrhythmia has not published.

CONCLUSION

This meta-analysis reveals that compared with ACEI/ARB therapy, SV therapy can reduce the risks of most arrhythmias, just the significant differences were revealed in reducing the risks of VT, severe arrhythmias, and cardiac arrest among patients with HFrEF. Besides, the positive effect of SV on VF according to statistical result of combining VF with cardiac arrest in patients with HFrEF is credibility. The result of our study provides more useful information for strengthening the clinical application of SV, especially among patients with high-risk factors for VT, VF, cardiac arrest, etc. By comparing with ACEI/ARB, we can infer that the additional antiarrhythmic effect of SV may originate from the increase of endogenous vasoactive peptides through inhibiting neprilysin. Of course, the exact mechanism and beneficiary population of SV therapy on arrhythmia need to be further clarified by further studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

REFERENCES

- 1. Vukmir RB. Cardiac arrhythmia diagnosis. *Am J Emerg Med.* (1995) 13:204–10. doi: 10.1016/0735-6757(95)90095-0
- Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. (2019) 73:2328–44. doi: 10.1016/j.jacc.2019.02.045
- 3. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. *Lancet.* (2015) 386:154–62. doi: 10.1016/S0140-6736(14)61774-8
- Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association[J]. *Circulation*, (2019) 139:e56–e528. doi: 10.1161/CIR.00000000000 0659
- Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. *Med Clin North Am.* (2012) 96:987–1000. doi: 10.1016/j.mcna.2012.07. 007
- 6. Gillis AM. Atrial fibrillation and ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. *Circulation.* (2017) 135:593–608. doi: 10.1161/circulationaha.116.025312
- Saltzman HE. Arrhythmias and heart failure. Cardiol Clin. (2014) 32:125–33. doi: 10.1016/j.ccl.2013.09.005
- Anselmino M, De Ferrari GM. Future perspectives and new "Frontiers" in cardiac rhythmology. *Front Cardiovasc Med.* (2020) 7:126. doi: 10.3389/fcvm. 2020.00126
- 9. Desai AS, Mcmurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. *Eur Heart J*. (2015) 36:1990–7. doi: 10.1093/eurheartj/ehv186

ETHICS STATEMENT

All procedures strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). All included studies were published without ethical and informed consent dispute.

AUTHOR CONTRIBUTIONS

RW, HY, JW, and LM contributed to the literature database search, data collection, data extraction, data analysis, and writing of the manuscript. RW, HY, JW, and YW performed data analysis of the results. XZ and LW were conceptualized the topic. XZ and LW reviewed and revised this article. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Talent introduction funding project of the First Affiliated Hospital of Jinan University (no. 808026).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm. 2022.890481/full#supplementary-material

- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. (2014) 371:993–1004. doi: 10.1056/nejmoa1409077
- 11. Crea F. The ESC guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy. *Eur Heart J.* (2021) 42:3581–5. doi: 10.1093/eurheartj/ehab627
- 12. Russo V, Bottino R, Rago A, Papa AA, Liccardo B, Proietti R, et al. The effect of sacubitril/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator. *J Clin Med.* (2020) 9:1111. doi: 10.3390/jcm9041111
- 13. Tsai YN, Cheng WH, Chang YT, Hsiao YW, Chang TY, Hsieh YC, et al. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia. *J Cardiol.* (2021) 78:275–84. doi: 10.1016/j.jjcc.2021.04.011
- Curtain JP, Jackson AM, Shen L, Jhund PS, Docherty KF, Petrie MC, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. *Eur J Heart Fail*. (2022) 24:551–61. doi: 10.1002/ejhf.2419
- Suo Y, Yuan M, Li H, Zhang Y, Li Y, Fu H, et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice. *Front Pharmacol.* (2019) 10:1285. doi: 10.3389/fphar.2019.01285
- Li SN, Zhang JR, Zhou L, Xi H, Li CY, Zhao L. Sacubitril/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2/3, p-JNK, and p-p38 signaling pathways. J Cardiovasc Transl Res. (2022) 15:131–42. doi: 10.1007/s12265-021-10137-5
- El-Battrawy I, Pilsinger C, Liebe V, Lang S, Kuschyk J, Zhou X, et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients. *J Clin Med.* (2019) 8:1582. doi: 10.3390/ jcm8101582

- Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. *Clin Res Cardiol.* (2019) 108:1074–82. doi: 10.1007/s00392-019-01440-y
- Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. (2019) 381:1609–20. doi: 10.1056/NEJMoa1908655
- 20. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med.* (2019) 380:1090. doi: 10.1056/NEJMx190009
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928
- 22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* (2002) 21:1539–58. doi: 10.1002/sim.1186
- Page MJ, Mckenzie JE, Kirkham J, Dwan K, Forbes A. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. *Cochrane Database Syst Rev.* (2014) 32:45–7. doi: 10.1016/j.enfi.2020.12.001
- 24. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. *J R Stat Soc.* (1988) 181:419–45. doi: 10.2307/2982993
- 25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj. 315.7109.629
- 26. Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (=65 Years) with systolic hypertension. *Am J Hypertens.* (2017) 30:1163–9. doi: 10.1093/ajh/hpx111
- 27. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. *Hypertension*. (2017) 69:411–20. doi: 10.1161/hypertensionAHA.116.08556
- Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet.* (2012) 380:1387–95. doi: 10.1016/S0140-6736(12)61227-6
- 29. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA*. (2019) 322:1077–84. doi: 10.1001/jama.2019.12843
- 30. Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). (2019) 21:67–76. doi: 10.1111/jch.13437
- Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. *Hypertens Res.* (2022) 45:824–33. doi: 10.1038/s41440-021-00819-7
- 32. Halle M, Schöbel C, Winzer EB, Bernhardt P, Mueller S, Sieder C, et al. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study. *Eur J Heart Fail.* (2021) 23:2073–82. doi: 10.1002/ejhf.2355
- 33. Wang Q, Zhuo C, Xia Q, Jiang J, Wu B, Zhou D, et al. Sacubitril/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation. *Cardiovasc Drugs Ther.* (2022). doi: 10.1007/s10557-022-07315-1
- 34. Wang H, Fu X. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. *Coron Artery Dis.* (2021) 32:418–26. doi: 10.1097/MCA. 00000000000932
- Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. *Circulation*. (2019) 139:1354–65. doi: 10.1161/circulationAHA.118.037077
- 36. Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, et al. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with

chronic heart failure with reduced ejection fraction. *Eur J Heart Fail.* (2021) 23:127–35. doi: 10.1002/ejhf.207

- 37. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction- results from the PARALLEL-HF study. *Circ J.* (2021) 85:584–94. doi: 10.1253/circj.CJ-20-0854
- 38. Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. *JAMA*. (2021) 326:1919–29. doi: 10.1001/jama.2021.18463
- Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: the PRIME study. *Circulation*. (2018) 139:1354–65. doi: 10.1161/circulationAHA.118. 037077
- 40. Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol. (2015) 6:187-214. doi: 10.1002/cphy.c140055
- Hanna P, Shivkumar K, Ardell JL. Calming the nervous heart: autonomic therapies in heart failure. *Card Fail Rev.* (2018) 4:92–8. doi: 10.15420/cfr.2018. 20.2
- 42. Chen CH. Critical questions about PARADIGM-HF and the future. Acta Cardiol Sin. (2016) 32:387–96. doi: 10.6515/acs20151120a
- 43. Diez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. *Eur J Heart Fail.* (2017) 19:167–76. doi: 10.1002/ejhf.656
- 44. Chang PC, Lin SF, Chu Y, Wo HT, Lee HL, Huang YC, et al. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarctioninduced heart failure rat model. *Cardiovasc Ther.* (2019) 2019:6032631. doi: 10.1155/2019/6032631
- 45. von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. *Circ Heart Fail.* (2015) 8:71–8. doi: 10.1161/circheartfailure.114. 001785
- 46. Iborra-Egea O, Gálvez-Montón C, Roura S, Perea-Gil I, Prat-Vidal C, Soler-Botija C, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. (2017) 3:12. doi: 10.1038/s41540-017-0013-4
- 47. Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kääb S, et al. Calciumhandling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. *Circ Arrhythm Electrophysiol.* (2008) 1:93–102. doi: 10.1161/CIRCEP.107.754788
- Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. *Physiol Rev.* (2007) 87:425–56. doi: 10.1152/physrev.00014. 2006
- Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachittiphan N, Link M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. *Heart Rhythm.* (2014) 11:1109–16. doi: 10.1016/j.hrthm.2014. 04.024
- Landstrom AP, Dobrev D, Wehrens XHT. Calcium signaling and cardiac arrhythmias. Circ Res. (2017) 120:1969–93. doi: 10.1161/circresaha.117.310083
- 51. Sung YL, Lin TT, Syu JY, Hsu HJ, Lin KY, Liu YB, et al. Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy. *ESC Heart Fail.* (2020) 7:4040–50. doi: 10.1002/ehf2.13013
- 52. Chang PC, Wo HT, Lee HL, Lin SF, Chu Y, Wen MS, et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmias inducibility in a rabbit myocardial infarction model. *J Card Fail.* (2020) 26:527–37. doi: 10.1016/j. cardfail.2020.03.007
- 53. Gallo G, Volpe M, Battistoni A, Russo D, Tocci G, Musumeci MB. Sacubitril/valsartan as a therapeutic tool across the range of heart failure phenotypes and ejection fraction spectrum. *Front Physiol.* (2021) 12:652163. doi: 10.3389/fphys.2021.652163
- Solomon SD, Vaduganathan MBLC, Packer M, Zile M, Swedberg K, Rouleau J, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. *Circulation*. (2020) 141:352–61. doi: 10.1161/circulationAHA.119. 044586

- 55. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. *Nat Rev Cardiol.* (2020) 17:559–73. doi: 10.1038/s41569-020-0363-2
- 56. Krebs C. Frequency and significance of ventricular arrhythmia in patients with reduced ejection fraction (less than or equal to 30%). *J Am Coll Cardiol.* (1987) 10:717–8. doi: 10.1016/s0735-1097(87) 80220-6
- Linton NW. Arrhythmia and left ventricular ejection fraction: once broken, always broken? *Heart Rhythm.* (2013) 10:847–8. doi: 10.1016/j.hrthm.2013.03. 018
- Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the cardiac arrhythmia suppression trial. *J Am Coll Cardiol.* (1995) 25:1250–7. doi: 10.1016/0735-1097(94)00553-3
- 59. Cameli M, Mandoli GE, Loiacono F, Sparla S, Iardino E, Mondillo S. Left atrial strain: a useful index in atrial fibrillation. *Int J Cardiol.* (2016) 220:208–13. doi: 10.1016/j.ijcard.2016.06.197

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Ye, Ma, Wei, Wang, Zhang and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.